Executive Roundtable: Industry Leaders Predict the Next Five Years of Extraction Regulation

Executive Summary

The next five years could reshape how cannabis, hemp, mushroom, botanical, and functional ingredient extracts are manufactured, tested, packaged, and commercialized in the United States. For businesses converting extracts into beverages, gummies, edibles, dietary supplements, topicals, cosmetics, and wellness products, regulatory strategy will increasingly influence facility investment, production costs, supply-chain decisions, and market access.

The precise direction of future regulation remains uncertain. Federal policy, state-level requirements, product classification, and enforcement priorities may evolve at different speeds. However, several operational priorities are already clear: stronger quality systems, defensible testing programs, reliable supplier documentation, improved manufacturing controls, and facilities designed around the products and processes they must support.

For this executive roundtable, NextBLDG examines the next five years through four industry perspectives: regulatory compliance, legal and policy strategy, manufacturing operations, and facility engineering. Rather than attributing invented quotations or predictions to individual experts, this analysis presents an evidence-based outlook on the issues these professionals should be evaluating.

The central conclusion is straightforward: companies that build compliance into their operating models will be better positioned to adapt than those that treat regulatory requirements as an afterthought.

1. Federal Regulation Will Remain a Major Strategic Variable

For extraction businesses, federal regulation is not a single issue. It is a combination of agricultural rules, food and dietary supplement requirements, controlled-substance laws, product-specific restrictions, labeling obligations, and state licensing frameworks.

The U.S. Department of Agriculture (USDA) oversees domestic hemp production under its hemp program, including licensing, recordkeeping, sampling, testing, and disposal requirements. Once hemp leaves the farm and enters downstream manufacturing and commerce, other regulatory frameworks may apply. The Food and Drug Administration (FDA), along with state and local authorities, has responsibilities that depend on the product and activity involved.

This division matters because a hemp crop that meets applicable agricultural requirements does not automatically make every product manufactured from it lawful to sell.

Over the next five years, manufacturers should prepare for continued scrutiny of product classification, ingredient composition, labeling, and the distinction between agricultural compliance and finished-product compliance.

What compliance leaders will be watching

Three questions will remain central to regulatory planning:

• What is the legal status of the ingredient? Source material, extraction methods, chemical composition, and intended use can affect the applicable requirements.
• What category does the finished product occupy? Foods, dietary supplements, cosmetics, drugs, and state-regulated cannabis products do not necessarily follow the same rules.
• Where will the product be manufactured and sold? State requirements, licensing conditions, distribution restrictions, and interstate commerce considerations may differ.

FDA’s existing framework for foods and dietary supplements illustrates why these distinctions matter. Food facilities subject to applicable requirements may need current good manufacturing practices (CGMPs), hazard analysis, risk-based preventive controls, and associated records. Dietary supplement manufacturers generally must comply with the applicable requirements of 21 CFR Part 111, with additional food CGMP requirements under Part 117 applying where required and not in conflict.

These are established frameworks, not hypothetical future obligations. Businesses should evaluate their current responsibilities before making investment decisions based on anticipated legislative changes.

Five-year outlook: Regulatory uncertainty may persist, but the operational value of understanding product classification, maintaining documentation, and monitoring federal and state developments is already measurable in risk reduction and business continuity.

2. Attorneys Will Need to Translate Policy Into Business Decisions

Legislative developments frequently generate headlines before they produce clear operating instructions. For executives, the challenge is distinguishing a proposed policy change from an enacted law, an effective regulation, or an enforcement decision.

This distinction is particularly important for hemp-derived cannabinoids and intoxicating products. Changes to federal hemp definitions, cannabinoid restrictions, or related product provisions could affect ingredient sourcing, formulation choices, inventory management, distribution agreements, and the commercial viability of existing product lines.

However, companies should not treat a proposal, legislative announcement, or anticipated rule as permission to change operations. Legal interpretation must account for the actual statutory language, effective dates, implementing rules, court decisions, and applicable state law.

Legal questions that deserve executive attention

Over the next five years, counsel and compliance teams should routinely assess:

1. Product eligibility: Does the ingredient and finished formulation qualify for the intended market and product category?
2. Claims and labeling: Are ingredient declarations, serving information, warnings, and marketing claims supportable and appropriate for the product?
3. Distribution: Can the product be sold in the intended states and through the proposed channels?
4. Contracts: Do supplier, manufacturer, distributor, and retailer agreements allocate responsibility for testing, recalls, regulatory changes, and nonconforming products?
5. Insurance and financing: Do the company’s regulatory exposure and business model align with its insurance coverage, lender requirements, and investment assumptions?

A useful approach is to establish a formal regulatory change-management process. Assign responsibility for monitoring relevant developments, documenting their status, determining applicability, and approving any resulting operational changes.

For example, if a new restriction could affect a cannabinoid ingredient, a manufacturer should know which products use that ingredient, which suppliers provide it, how much inventory is on hand, and what contractual obligations could be triggered. That information should be available before a change takes effect, not reconstructed during a crisis.

Five-year outlook: Legal expertise will remain essential, but its greatest value will come from connecting policy interpretation to practical decisions about products, capital expenditure, inventory, and market access.

3. Quality Systems Will Become a Competitive Differentiator

Extraction manufacturers often focus on potency, yield, and production efficiency. Those measures remain important, but they cannot establish product quality on their own.

A commercially reliable ingredient must also meet appropriate specifications for identity, composition, contaminants, and other characteristics relevant to its intended use. The finished product must then maintain those characteristics through formulation, processing, packaging, transportation, and storage.

For companies entering food, supplement, or other regulated consumer-product markets, quality systems are not simply a response to inspections. They are part of the infrastructure required to manufacture consistently.

FDA’s dietary supplement CGMP framework under 21 CFR Part 111 includes requirements for specifications, production and process controls, quality control operations, packaging and labeling, and recordkeeping. Applicable food manufacturing requirements may also include hazard analysis and preventive controls under 21 CFR Part 117.

The next phase of quality management

Over the coming years, manufacturers should expect continued business pressure to demonstrate that their quality systems are effective, documented, and appropriate to their products.

Priority areas include:

• Supplier qualification: Verify ingredient identity, manufacturing practices, traceability, and the reliability of supplier documentation.
• Validated or otherwise appropriately verified processes: Establish evidence that critical process parameters consistently produce material meeting specifications.
• Risk-based testing: Select analytical methods and testing frequencies according to ingredient risks, product characteristics, applicable rules, and intended use.
• Deviation management: Investigate out-of-specification results, process failures, and unexpected events before releasing affected material.
• Change control: Assess the impact of new suppliers, formulations, equipment, process parameters, and packaging materials.
• Traceability and recall readiness: Maintain records that support timely identification of affected ingredients, batches, and distribution destinations.

Testing deserves particular attention. A certificate of analysis (COA) can be valuable evidence, but its usefulness depends on factors such as sample representativeness, method suitability, laboratory competence, analyte coverage, and chain of custody. A COA should not be treated as a universal guarantee of safety or legal compliance.

Manufacturers should also distinguish between the quality of an extract and the quality of the finished product. An extract that meets its own specifications can still create problems when incorporated into a beverage, gummy, emulsion, or topical formulation.

Five-year outlook: Quality programs that connect incoming materials, in-process controls, finished-product testing, and distribution records will provide stronger support for regulatory compliance and customer confidence.

4. Facility Design Will Need to Anticipate Regulatory and Product Changes

Facility decisions can lock a manufacturer into operating constraints for years. In extraction and downstream production, those constraints may include incompatible process flows, insufficient utility capacity, inadequate ventilation, limited sanitation access, poor material segregation, or insufficient space for quarantine and finished-goods storage.

Retrofitting these deficiencies after production begins can be expensive and disruptive.

A forward-looking facility strategy should begin with the intended products, extraction technologies, process hazards, cleaning requirements, and applicable regulatory framework. The building and its mechanical, electrical, plumbing, ventilation, and process systems should support those needs from the outset.

Four facility priorities for the next five years

1. Process flow and contamination prevention

Facilities should be arranged to reduce the risk of mix-ups, cross-contamination, and uncontrolled movement of people, materials, waste, and finished goods. Depending on the operation, this may require dedicated areas, controlled access, physical separation, or documented cleaning and changeover procedures.

2. Mechanical and utility capacity

Extraction and formulation processes may require specialized ventilation, temperature control, compressed gases, water treatment, drainage, electrical service, or other utilities. Capacity should be based on actual equipment loads and anticipated production requirements rather than rough estimates.

Where flammable solvents or other hazardous materials are involved, process-specific fire protection, electrical classification, ventilation, storage, and occupational safety requirements must be evaluated by qualified professionals and the relevant authorities.

3. Sanitation and maintainability

Equipment should be accessible for inspection, cleaning, maintenance, and verification. Drainage, surface finishes, material selection, and room layouts should reflect the actual process and the contamination hazards associated with it.

4. Flexibility without unnecessary complexity

Modular equipment, adaptable utility connections, and carefully planned expansion areas can improve flexibility. However, flexible space must not compromise segregation, safety, sanitation, or applicable licensing conditions.

Facility planning should involve engineering, operations, quality assurance, environmental health and safety, and regulatory personnel before major design decisions are finalized.

Five-year outlook: The most resilient facilities will not necessarily be the largest or most automated. They will be the facilities whose layouts, utilities, and quality systems align with their validated operating needs and can accommodate justified changes without compromising compliance.

5. Extraction Technology Will Advance Alongside Process-Control Expectations

Extraction technology will continue to evolve as manufacturers seek improved selectivity, consistent ingredient profiles, lower operating costs, reduced waste, and better integration with downstream formulation.

Supercritical carbon dioxide extraction, ethanol extraction, hydrocarbon extraction, and other botanical processing methods each offer different advantages and constraints. The appropriate technology depends on the target compounds, feedstock, desired purity, throughput, economics, solvent-management requirements, and the characteristics of the final product.

The industry should be cautious about assuming that a newer extraction method automatically provides a regulatory advantage. A process still needs to be suitable for its intended purpose, safely engineered, properly controlled, and supported by appropriate analytical evidence.

What operators should prioritize

Over the next five years, manufacturers should evaluate technology investments against more than extraction yield.

Important measures include:

• Batch-to-batch consistency and ingredient specifications.
• Solvent recovery, consumption, and residual-solvent controls where applicable.
• Energy and water consumption per unit of saleable output.
• Equipment cleaning, maintenance, and changeover time.
• Operator exposure and process safety.
• Analytical testing requirements and production release timelines.
• Compatibility with downstream emulsification, encapsulation, drying, or formulation.

Automation and digital process monitoring may improve repeatability, but only when the data are reliable and the systems are appropriately maintained. Electronic records, instrument calibration, access controls, backup procedures, and change management should be considered alongside the equipment itself.

A manufacturer that increases throughput without improving process control may simply produce nonconforming material faster.

Five-year outlook: Competitive advantage will increasingly depend on the combination of extraction technology, process engineering, quality assurance, and downstream product performance—not on extraction yield alone.

6. Product Commercialization Will Depend on Getting Classification and Claims Right

One of the most important decisions a manufacturer makes occurs before production: determining how the finished product will be marketed.

A botanical extract can be incorporated into products with very different regulatory requirements. A topical cosmetic, a conventional beverage, a dietary supplement, and a therapeutic product are not interchangeable categories simply because they contain similar ingredients.

The intended use, composition, claims, and applicable laws help determine the regulatory framework. Manufacturers should establish that framework early, before finalizing a formulation, investing in packaging, or committing to distribution agreements.

Claims can create regulatory exposure

Consider a topical botanical balm marketed to moisturize skin. Depending on its composition and presentation, it may qualify as a cosmetic. If its labeling or advertising claims that it treats a disease or affects the body’s structure or function, it may instead be subject to drug requirements.

FDA explains that cosmetic claims must be truthful and not misleading, and that therapeutic claims can change how a product is regulated. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) also established additional responsibilities involving safety substantiation, adverse-event reporting, facility registration, and product listing, subject to applicable exemptions and requirements.

For cannabis-derived ingredients, the distinction can be even more consequential. FDA’s published position is that CBD and THC products are excluded from the dietary supplement definition under the statutory provision it cites, absent an applicable regulatory exception. FDA has also stated that adding CBD or THC to conventional food is generally prohibited under the relevant federal framework, subject to the specific legal circumstances.

These issues should be reviewed against current FDA guidance and applicable law before a product is commercialized.

A practical commercialization checklist

Before launching a new product, manufacturers should confirm:

• The intended regulatory category and permitted market.
• Ingredient eligibility and the status of any required notifications or authorizations.
• Product safety, identity, purity, strength, and composition specifications as applicable.
• Labeling, serving information, warnings, and substantiation for marketing claims.
• Packaging compatibility, product stability, and shelf-life support.
• Required registrations, licenses, testing, and manufacturing records.
• A process for monitoring post-market complaints and adverse events where applicable.

Five-year outlook: Commercialization teams will need to work more closely with legal, quality, formulation, packaging, and operations personnel. Product development that considers compliance only after formulation is complete may face expensive redesigns and delayed launches.

7. The Economics of Compliance Will Influence Investment Decisions

Regulatory compliance creates costs, but failures can also produce substantial indirect expenses: rejected batches, idle production lines, product recalls, lost retail relationships, legal disputes, and interrupted distribution.

For investors and business owners, the relevant question is not simply how much a compliance program costs. It is how that cost compares with the financial exposure associated with inadequate controls.

The answer will vary by product category, production volume, facility type, and market. Companies should avoid assuming that a single certification or testing expense represents the full cost of operating compliantly.

Build compliance into the financial model

A realistic operating budget should account for:

• Licensing, legal review, and regulatory monitoring.
• Quality personnel, training, documentation, and supplier qualification.
• Analytical testing, reference standards, and laboratory services.
• Facility maintenance, ventilation, sanitation, and process safety.
• Equipment calibration, maintenance, and replacement.
• Packaging and labeling reviews.
• Product holds, investigations, and potential recall costs.
• Future facility upgrades and changes to production processes.

Manufacturers should also measure the cost of quality through indicators such as batch rejection rates, deviations, unplanned downtime, retesting, production yield, and complaint frequency.

These indicators help distinguish productive compliance spending from recurring process failures. For example, repeated out-of-specification results may indicate a supplier problem, inconsistent extraction parameters, unsuitable sampling, or an ineffective analytical method. The solution may require process redesign rather than simply increasing testing frequency.

Smaller manufacturers can benefit from phased investment, provided the approach meets applicable requirements and does not leave critical risks uncontrolled. Priorities should be determined by product risk, regulatory obligations, and the consequences of failure.

Five-year outlook: Investors and lenders may place greater emphasis on documented operating controls, regulatory readiness, and the cost of maintaining a compliant facility. Companies that can demonstrate reliable production and credible quality records will be better equipped to explain their risk profile.

8. A Five-Year Planning Framework for Industry Leaders

Although no forecast can establish exactly how federal or state rules will change, businesses can prepare for multiple plausible outcomes.

The following framework turns broad regulatory uncertainty into a manageable operating plan.

Planning horizon	Priority actions	Intended outcome
Next 12 months	Audit product classifications, licenses, supplier records, testing programs, and facility risks.	Establish a documented baseline and identify critical gaps.
Years 1–2	Strengthen quality systems, change control, traceability, and regulatory monitoring.	Improve consistency and reduce avoidable compliance failures.
Years 2–3	Evaluate equipment, utilities, digital records, and facility capacity against forecast production needs.	Support growth without creating unnecessary compliance debt.
Years 3–4	Reassess formulations, suppliers, packaging, and distribution plans against confirmed regulatory developments.	Maintain flexibility as market conditions change.
Years 4–5	Review capital plans, quality performance, product portfolios, and expansion opportunities.	Align long-term investment with demonstrated operating capabilities.

This is a recommended planning model, not a prediction of when particular laws will take effect.

Executives should review the framework at least annually and whenever a material legal, regulatory, or operational development affects the business.

A cross-functional review team should include executive leadership, legal counsel, regulatory affairs, quality assurance, manufacturing, engineering, procurement, and finance. For smaller companies, several responsibilities may be handled by the same person or supported by outside specialists.

The goal is to ensure that regulatory decisions translate into specific actions, assigned responsibilities, deadlines, and documented approvals.

9. Questions Industry Leaders Should Be Asking Now

A productive executive roundtable should move beyond broad predictions and examine the decisions that organizations can make today.

The following questions can guide discussions among attorneys, compliance specialists, extraction operators, facility engineers, and investors.

For regulatory and legal experts

• Which proposed or enacted policy changes could materially affect our product portfolio?
• What is the difference between a confirmed legal requirement and a potential future obligation?
• Which ingredients, claims, or distribution channels carry the greatest unresolved regulatory risk?
• What events should trigger an immediate legal and compliance review?

For extraction and manufacturing operators

• Which process parameters have the greatest influence on batch consistency?
• Can the facility reliably trace raw materials through extraction, formulation, packaging, and distribution?
• What are the main causes of rejected batches, delays, and unplanned downtime?
• How quickly can production adapt if a supplier or ingredient becomes unavailable?

For quality and laboratory professionals

• Are sampling plans and analytical methods appropriate for the materials being tested?
• Do supplier COAs provide sufficient evidence for the intended application?
• Are deviations investigated to identify root causes and prevent recurrence?
• Can the company demonstrate that released products meet established specifications?

For engineers and facility planners

• Does the facility support safe material flow, sanitation, ventilation, and process segregation?
• Are utilities and equipment suitable for anticipated production volumes?
• Which design limitations would make future regulatory or process changes expensive?
• Can planned expansion occur without compromising existing operations?

For executives and investors

• What is the financial impact of a product hold, recall, or regulatory change?
• Which compliance investments reduce the most significant operational risks?
• Does the company have a realistic budget for maintenance, quality assurance, and future facility modifications?
• Are growth projections based on products and markets the company can lawfully serve?

These questions provide a practical basis for discussion without relying on speculative claims about the precise timing or direction of future regulation.

Conclusion: Prepare for Change Without Waiting for Certainty

The next five years will present extraction businesses with both opportunities and challenges. Advances in extraction technology, formulation, automation, and ingredient science may create new commercial possibilities. At the same time, regulatory developments, product-classification questions, testing expectations, and market-specific requirements will continue to influence how those opportunities can be pursued.

The most useful forecast is not that every company will face the same rules or that regulation will inevitably become stricter in every area. Rather, successful businesses will need to become more capable of identifying applicable requirements, assessing risk, documenting decisions, and adapting their operations when the legal or commercial environment changes.

For manufacturers, this means investing in quality systems that extend beyond final-product testing. For attorneys and compliance professionals, it means translating legal developments into clear operating guidance. For engineers, it means designing facilities around safety, process control, sanitation, and maintainability. For executives and investors, it means evaluating compliance as a core component of operational resilience.

The companies best positioned for the next five years will be those that can demonstrate not only what their products contain, but also how those products are manufactured, tested, controlled, and brought to market.

In an evolving extraction industry, regulatory readiness is not a one-time project. It is an ongoing management discipline.